Supported by
Built on a breakthrough
CapsulateBio was founded on a breakthrough born in the Langer and Traverso Labs at MIT, where pioneering research laid the foundation for a new era of oral drug delivery. CapsulateBio's category-defining drug delivery platform is capable of reshaping how biologics are administered globally.
A new paradigm for oral biologic delivery
For decades, the gastrointestinal barrier has limited the oral delivery of biologics. Conventional oral technologies rely on chemical absorption enhancers that deliver less than 5% bioavailability, making them unsuitable for most biologics. CapsulateBio has created simple-to-swallow robotic pills.
CapsulateBio’s oral platforms are designed to do more than replace injections with a more convenient oral option. By enabling delivery of therapeutically relevant doses with injectable-like bioavailability, our platform has the potential to preserve and enhance the safety and efficacy of today’s leading biologics. This creates new opportunities to optimize dosing, improve patient adherence, reduce pharmacokinetic variability, and expand the therapeutic potential of biologics for patients worldwide.
™
Oral Administration Platform
Delivers liquid biologics directly into the wall of the small intestine where conditions are ideal for systemic absorption, overcoming the gastrointestinal barrier that has long limited oral biologic delivery.
™
Oral Administration Platform
Delivers solid biologics directly into the wall of the stomach using a self-orienting robotic pill, overcoming the gastrointestinal barrier that has long limited oral biologic delivery.
